Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 85.00
Bid: 70.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 30.00 (42.857%)
Open: 85.00
High: 85.00
Low: 85.00
Prev. Close: 85.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

19 Dec 2008 07:01

RNS Number : 4235K
Stanelco PLC
19 December 2008
 



19 December 2008

Stanelco plc ('Stanelco' or 'the Company')

Appointment of Group Finance Director

The Board of Directors (the 'Board') of Stanelco, the Bioplastics and Radio Frequency (RF) technology business, is pleased to announce the appointment of Susan "Sue" Bygrave, aged 43, as Group Finance Director and member of the Board with effect from 5 January 2009.

Prior to joining Stanelco, Sue held the position of Group Finance Director of VEGA Group plc ("VEGA"), the specialist professional services group providing clients with consulting, technology and managed solutions business. VEGA floated on the London Stock Exchange in 1992 and was listed on the FTSE Fledgling Index (Software and Computer Services classification) and the FTSE techMark Index. Following flotation, VEGA achieved growth both organically and by acquisition, until it was acquired in February 2008, by Finmeccanica SpA for £62m, and consequently de-listed.

Prior to this, Sue worked for Mettoni Group plc, DCS Group plc and KPMG with whom she qualified as a chartered accountant.

John Standen, Chairman of Stanelco, commented:

"Sue joins Stanelco at an exciting time and we are delighted to welcome her. The Board is confident that Sue's pragmatic approach and proven track-record in organic and acquisitive growth, as well as her established plc experience, will be invaluable at this important stage of Stanelco's pursuit of significant growth in the bioplastics sector".

Sue Bygrave, incoming Group Finance Director of Stanelco, commented:

"I am delighted to be joining Stanelco at this exciting time in its evolution and I look forward to working with the Board as we pursue the market opportunities and grow the business."

Further information on Ms Susan Jane Bygrave is set out below:

Sue Bygrave's directorships in the last five years (from which she has now resigned) comprise VEGA Group plc and Mettoni Group plc. In July 2002, while Sue Bygrave was a Director of the company, Mettoni Group plc was placed into administrative receivership.

Sue Bygrave does not have an interest in the ordinary shares of the Company.

Other than the information contained in this announcement, there are no other matters to be disclosed under paragraph 9.6.13R of the Listing Rules.

For further information please contact:

Paul Mines, Chief Executive, Stanelco 

Tel: +44 (0) 2380 867100

Jonathon Brill/Caroline Stewart

Financial Dynamics

Tel: +44 (0) 20 7831 3113

About Stanelco 

Stanelco is a market-leading British technology company at the forefront of development and commercialisation of bioplastics. Stanelco produces a biodegradable and sustainable range of products under the Bioplast brand. Such products are capable of replacing conventional oil-based plastics and have diverse application including flexible films, moulded products, extruded sheets and food wraps. In addition, Stanelco's separate Radio Frequency (RF) division has worldwide renown in the design and install of specialist RF furnaces, welders and induction equipment.

 

Stanelco already has some 200 patents and its future success relies on the expertise of its highly qualified commercial, research and development teams that are focusing on the invention and industrialisation of new biopolymer-based resins and on delivering products with ever greater functionality and sustainability.

Ends

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATPBFTMMMBBJP
Date   Source Headline
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.